Esperion Therapeutics

Landos Biopharma Announces Leadership Transition

Retrieved on: 
Lunedì, Novembre 8, 2021
Steps, Medtech, University, Immunity, Business, Industry, COO, Therapy, Strategic management, Esperies, Pfizer, Leadership, Clinical trial, Ulcerative colitis, Northwestern University, NASDAQ, CEO, Association of British HealthTech Industries, Capital, Investment, Rheumatoid arthritis, Esperion Therapeutics, NLRX1, Psoriasis, Eosinophilic esophagitis, Bempedoic acid, Ross School of Business, Interim, CFO, Board, LANCL2, Acquisition, Company, GLOBE, Metabolism, Degenerative disease, PLXDC2, A.I, Independent Board for Presbyterian Foreign Missions, Patient, Marketing, Atopic dermatitis, Risk, Sarepta Therapeutics, Management, Pharmaceutical industry

BLACKSBURG, Va., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel oral small-molecule therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Ph.D., has stepped down as Chairman, President and Chief Executive Officer, effective immediately. Tim M. Mayleben, a member of the Landos Board, has been appointed Interim President and CEO. Chris Garabedian, also a Landos Director, has been appointed Chairman of the Board. Dr. Bassaganya-Riera will serve as an advisor to the Company to ensure a smooth transition.

Key Points: 
  • Under his visionary leadership, Landos has made tremendous progress advancing and expanding its pipeline of first-in-class oral therapeutics for patients with autoimmune diseases.
  • With seven product candidates in the pipeline across three novel mechanisms, Josep and the Board agree that this is the right time to transition to our next phase of leadership.
  • With Tims leadership, we believe Landos is well positioned to continue advancing as we work to identify Joseps successor.
  • Landos Biopharma has 17 active development programs targeting these novel pathways at the interface of immunity and metabolism.

Esperion Reports Third Quarter 2021 Financial Results and Provides Company Update

Retrieved on: 
Martedì, Novembre 2, 2021
Guideline, Twitter, U.S. Securities and Exchange Commission, Cardiovascular disease, Cleveland, Â, Daiichi Sankyo, Research and development, COVID-19, Program, Therapy, GLOBE, Ezetimibe, Research, CVD, Security (finance), Moyamoya disease, Atherosclerosis, Tablet, Stroke, Administration, Physician, Pharmacy, Hypercholesterolemia, Bempedoic acid, Cholesterol, National Cholesterol Education Program, Treasury, Exercise, Risk, Esperion Therapeutics, Disease, CEO, Environment, Growth, Population, MACE, General officer, Patient, ANN, Prescription, ESPR, NASDAQ, Quarter, Adult, Forward-looking statement, Development, Mortality, Pharmaceutical industry, Animal, Lithium, Risk management

ANN ARBOR, Mich., Nov. 02, 2021 (GLOBE NEWSWIRE) --  Esperion (NASDAQ: ESPR) today reported financial results for the third quarter ended September 30, 2021 and provided a business update.

Key Points: 
  • Royalty revenue for the third quarter 2021 was $1.2 million and $2.8 million for the nine months ended September 30, 2021.
  • The increase in total revenue in the third quarter of 2021 was primarily attributable to prescription growth of NEXLETOL and NEXLIZET.
  • The decrease in the third quarter of 2021 was primarily attributable to a decrease in commercial compensation expense.
  • Esperion will host a conference call and webcast today, November 2, 2021 at 8:00 A.M. Eastern Time to provide a third quarter 2021 financial results and company update.

Checkmate Pharmaceuticals Announces CEO Transition

Retrieved on: 
Mercoledì, Ottobre 27, 2021
Financial condition report, Melanoma, Eli Lilly, U.S. Securities and Exchange Commission, Biotechnology, CpG, LinkedIn, CFO, Securities Act of 1933, Â, Twitter, File, Analysis, Sustainability Accounting Standards Board, Security (finance), Private Securities Litigation Reform Act, Result, Audit committee, TLR9, Agriculture, PricewaterhouseCoopers, SEC, Business administration, AbbVie, Agricultural economics, Review, Montana State University, Social media, Daiichi Sankyo, Annual report, Forward-looking statement, Company, CEO, Board, COVID-19, Growth, Esperies, Nasdaq, Immune system, Therapy, MicroRNA, GLOBE, Cooper, Sale, Esperion Therapeutics, Pharmaceutical industry

CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (Checkmate), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Alan Fuhrman has been appointed as interim President and CEO.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (Checkmate), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Alan Fuhrman has been appointed as interim President and CEO.
  • Mr. Fuhrman succeeds Barry Labinger, who has transitioned from his roles as President and CEO and Director.
  • Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer.
  • The information that Checkmate Pharmaceuticals posts on these channels and websites could be deemed to be material information.

Reneo Pharmaceuticals Appoints Ashley Hall as Chief Development Officer

Retrieved on: 
Lunedì, Ottobre 11, 2021
NASDAQ, Private Securities Litigation Reform Act, Juris, Therapy, Ultragenyx, PCSK9, Law, McArdle, Biochemistry, Myopathy, Metabolism, JD, GLOBE, MedImmune, Regulatory affairs, University of California, San Diego, PMM, U.S. Securities and Exchange Commission, University, Glycogen storage disease type V, University of San Diego School of Law, Degenerative disease, Mitochondrion, Cell biology, Philosophy, Security (finance), ATP, Bioethics, Esperion Therapeutics, Adenosine triphosphate, Gene, AstraZeneca, Amgen, Leadership, CEO, Financial compensation, Abraxis BioScience, Patient, Pharmaceutical industry

IRVINE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic mitochondrial diseases, today announced the appointment of Ashley F. Hall, JD, to the position of Chief Development Officer.

Key Points: 
  • IRVINE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic mitochondrial diseases, today announced the appointment of Ashley F. Hall, JD, to the position of Chief Development Officer.
  • In this role, Ms. Hall will oversee nonclinical and clinical operations, global regulatory affairs, pharmaceutical development, and program management for all the companys development programs.
  • We are happy to welcome Ashley to the Reneo leadership team, said Gregory J. Flesher, President and CEO of Reneo Pharmaceuticals.
  • Her deep understanding of the drug development process will be instrumental in the development of REN001.

Update -- Pharma Two B Appoints Jeffrey Berkowitz as Chairman of its Board of Directors

Retrieved on: 
Lunedì, Agosto 23, 2021
PD, Company, UnitedHealth Group, Richard Barker (life sciences and healthcare leader), Pramipexole, Group, Therapy, Brooklyn Law School, Parkinson, Acquisition, Union College, GLOBE, International, Schering-Plough, Walgreens Boots Alliance, Board of directors, Parkinson's disease, Merck & Co., Merck, Esperies, Commerce, Marketing, Alliance, Alliance Boots, Development, Gesellschaft mit beschränkter Haftung, List of life sciences, Board, Safety, Risk, Esperion Therapeutics, Patient, CEO, FDA, Pharmacy, Schering, Pharma, Technology, Pharmaceutical industry, Management

I am delighted to welcome Jeff as Chairman of Pharma Two Bs Board of Directors, said Dr. Sheila Oren, M.D., M.B.A., Chief Executive Officer of Pharma Two B.

Key Points: 
  • I am delighted to welcome Jeff as Chairman of Pharma Two Bs Board of Directors, said Dr. Sheila Oren, M.D., M.B.A., Chief Executive Officer of Pharma Two B.
  • Mr. Berkowitz commented, "I am impressed by Pharma Two Bs progress to date and honored to be appointed as Chairman.
  • I look forward to working closely with Sheila and the rest of the Board and contributing to the company's future success."
  • Pharma Two B is led by highly experienced team, supported by prominent scientific and clinical key opinion leaders, and backed by a dedicated group of investors.

Pharma Two B Appoints Jeffrey Berkowitz as Chairman of its Board of Directors

Retrieved on: 
Giovedì, Agosto 12, 2021
Alliance Boots, Walgreens Boots Alliance, Gesellschaft mit beschränkter Haftung, Merck & Co., Board of directors, UnitedHealth Group, Schering-Plough, Pramipexole, GLOBE, List of life sciences, Pharma, FDA, Alliance, Therapy, Safety, CEO, Esperion Therapeutics, Marketing, Parkinson's disease, Schering, Acquisition, Union College, Development, Parkinson, Technology, Company, Esperies, Risk, Merck, International, Brooklyn Law School, PD, Commerce, Board, Group, Pharmacy, Richard Barker (life sciences and healthcare leader), Patient, Pharmaceutical industry, Management

REHOVOT, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease (PD), today announced the appointment of Jeffrey Berkowitz as Chairman of its Board of Directors, effective immediately.

Key Points: 
  • REHOVOT, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease (PD), today announced the appointment of Jeffrey Berkowitz as Chairman of its Board of Directors, effective immediately.
  • I am delighted to welcome Jeff as Chairman of Pharma Two Bs Board of Directors, said Dr. Sheila Oren, M.D., M.B.A., Chief Executive Officer of Pharma Two B.
  • Mr. Berkowitz commented, "I am impressed by Pharma Two Bs progress to date and honored to be appointed as Chairman.
  • Pharma Two B is led by highly experienced team, supported by prominent scientific and clinical key opinion leaders, and backed by a dedicated group of investors.

ESPERION Reports Second Quarter 2021 Financial Results and Provides Company Update

Retrieved on: 
Martedì, Agosto 3, 2021
Esperion Therapeutics, Pfizer, Health care, Bempedoic acid, Clinical medicine, Ezetimibe, Organic compounds

ANN ARBOR, Mich., Aug. 03, 2021 (GLOBE NEWSWIRE) -- ESPERION (NASDAQ:ESPR), the lipid management company, today reported financial results for the second quarter ended June 30, 2021 and provided a business update.

Key Points: 
  • Prescriptions Grew 28% During the Quarter; More Than 47,800 Patients Have Filled a Prescription for NEXLETOL (bempedoic acid) Tablets or NEXLIZET (bempedoic acid and ezetimibe) Tablets
    ANN ARBOR, Mich., Aug. 03, 2021 (GLOBE NEWSWIRE) -- ESPERION (NASDAQ:ESPR), the lipid management company, today reported financial results for the second quarter ended June 30, 2021 and provided a business update.
  • Royalty revenue for the second quarter 2021 was $1.0 million and $1.6 million for the six months ended June 30, 2021.
  • Total revenue for the second quarter ended June 30, 2021 was $40.7 million and $48.6 million for the six months ended June 30, 2021, compared to $212.2 million and $214.1 million for the comparable periods in 2020.
  • ESPERION will host a conference call and webcast today, August 3, 2021 at 8:00 A.M. Eastern Time to provide a second quarter 2021 financial results and company update.

Esperion to Report Second Quarter 2021 Financial Results August 3, 2021

Retrieved on: 
Martedì, Luglio 13, 2021
American television shows, Esperion Therapeutics, Pfizer, Television in the United States, American television series, NASDAQ, Ann Arbor, Michigan, Today

ANN ARBOR, Mich., July 13, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report second quarter 2021 financial results before the open of the U.S. financial markets on Tuesday, August 3, 2021.

Key Points: 
  • ANN ARBOR, Mich., July 13, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report second quarter 2021 financial results before the open of the U.S. financial markets on Tuesday, August 3, 2021.
  • Following the release, company management will host a webcast and conference call at 8:00 a.m.
  • ET to discuss financial results and business progress.
  • A live audio webcast can be accessed on the investor and media section of the Esperion website at investor.esperion.com.

Viracta Therapeutics Announces the Appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer and Key Additions to Management Team

Retrieved on: 
Martedì, Luglio 6, 2021
Epstein–Barr virus, Infectious causes of cancer, Esperion Therapeutics, EBV, Ivor Royston, Lymphoma, Medical specialties, Health, Clinical medicine, Viral structural proteins

SAN DIEGO, July 6, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc.(Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer.

Key Points: 
  • SAN DIEGO, July 6, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc.(Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer.
  • "Ayman is one of the world's leading experts on Epstein-Barr virus (EBV)-associated cancers and a tremendous addition to our management team," said Ivor Royston, M.D., President and Chief Executive Officer of Viracta.
  • Our impressive clinical data has validated the approach, and I am thrilled to have the opportunity to join Viracta as Chief Scientific Officer at this very exciting time.
  • Patric Nelson, MBA,joined Viracta from Esperion Therapeutics, where he served as Vice President, Business Development and Alliance Management.

ESPERION Appoints JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer

Retrieved on: 
Lunedì, Giugno 28, 2021
Esperion Therapeutics, Pfizer

ANN ARBOR, Mich., June 28, 2021 (GLOBE NEWSWIRE) -- ESPERION (NASDAQ: ESPR), today announced the appointment of JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer, effective immediately.

Key Points: 
  • ANN ARBOR, Mich., June 28, 2021 (GLOBE NEWSWIRE) -- ESPERION (NASDAQ: ESPR), today announced the appointment of JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer, effective immediately.
  • She will serve as a member of the executive team and report to Sheldon Koenig, President and Chief Executive Officer.
  • Dr. Foody is a global expert with extensive clinical and medical experience in preventive cardiology, global medical development and medical affairs, which adds greatly to the depth of our management team, said Sheldon Koenig, President and Chief Executive Officer of ESPERION.
  • I am excited to have JoAnne join the ESPERION team and look forward to working with her.